Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 8/20 | 0.70 |
| ▸ | MAOB | P27338 | 7/20 | 0.61 |
| ▸ | MAOA | P21397 | 5/20 | 0.61 |
| ▸ | TLR2 | O60603 | 3/20 | 0.48 |
| ▸ | TLR1 | Q15399 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15094433 | 1.00 | KDM1A (0.70) | KDM1AMAOBMAOATLR2TLR1 | |
| SCHEMBL15149989 | 1.00 | KDM1A (0.70) | KDM1AMAOBMAOATLR2TLR1 | |
| SCHEMBL12242261 | 1.00 | KDM1A (0.70) | KDM1AMAOBMAOATLR2TLR1 | |
| SCHEMBL1524580 | 0.87 | KDM1A (0.61) | KDM1AMAOBMAOA | |
| SCHEMBL27991096 | 0.87 | KDM1A (0.61) | KDM1AMAOBMAOA | |
| SCHEMBL15099831 | 0.87 | KDM1A (0.71) | KDM1AMAOBMAOATLR2TLR1 | |
| SCHEMBL17718439 | 0.87 | KDM1A (0.71) | KDM1AMAOBMAOATLR2TLR1 | |
| SCHEMBL16019177 | 0.87 | KDM1A (0.71) | KDM1AMAOBMAOATLR2TLR1 | |
| SCHEMBL15235894 | 0.87 | KDM1A (0.71) | KDM1AMAOBMAOATLR2TLR1 | |
| SCHEMBL15096181 | 0.87 | KDM1A (0.71) | KDM1AMAOBMAOATLR2TLR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3495349-B1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2023-06-28 | — | — | EP | disclosed |
| EP-4074695-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | Oryzon Genomics, S.A. (ES) | 2022-10-19 | — | — | EP | disclosed |
| EP-3736265-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | Oryzon Genomics, S.A. (ES) | 2020-11-11 | — | — | EP | disclosed |
| EP-2768805-B1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2020-03-25 | — | — | EP | disclosed |
| US-10329256-B2 | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors | ORYZON GENOMICS, S.A. (ES) | 2019-06-25 | — | — | US | disclosed |
| EP-3495349-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | Oryzon Genomics, S.A. (ES) | 2019-06-12 | — | — | EP | disclosed |
| EP-2776394-B1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2018-12-26 | — | — | EP | disclosed |
| US-20180354902-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS S.A. (ES) | 2018-12-13 | — | — | US | disclosed |
| US-9944601-B2 | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors | ORYZON GENOMICS, S.A. (ES) | 2018-04-17 | — | — | US | disclosed |
| US-20180079709-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2018-03-22 | — | — | US | disclosed |
| US-20140256729-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2014-09-11 | — | — | US | disclosed |
| US-20130178520-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | DUKE UNIVERSITY (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130178520-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | DUKE UNIVERSITY (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130178520-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | DUKE UNIVERSITY (US) | 2013-07-11 | — | — | US | disclosed |
| EP-1848695-B1 | COMPOUNDS WHICH POTENTIATE GLUTAMATE RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LTD (GB) | 2011-07-27 | — | — | EP | disclosed |
| EP-1848695-B1 | COMPOUNDS WHICH POTENTIATE GLUTAMATE RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LTD (GB) | 2011-07-27 | — | — | EP | disclosed |
| US-7790758-B2 | glutamate receptors agonists; especially to treat psychotic conditions, including schizophrenia and enhancement of cognition; N-{-2-[4-(6-fluoro-3-pyridinyl)phenyl]cyclopropyl}-2-propanesulfonamide; stereoselectively epoxidising a suitable styrene; coupling with boronic acid derivatives | GLAXO GROUP LIMITED (GB) | 2010-09-07 | — | — | US | disclosed |
| US-20080167351-A1 | Compounds Which Potentiate Glutamate Receptor and Uses Thereof in Medicine | GLAXO GROUP LIMITED (GB) | 2008-07-10 | — | — | US | disclosed |
| EP-1848695-A1 | COMPOUNDS WHICH POTENTIATE GLUTAMATE RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2007-10-31 | — | — | EP | disclosed |
| WO-2006087169-A1 | COMPOUNDS WHICH POTENTIATE GLUTAMATE RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2006-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180354902-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | KDM1A 2/4885MAOB 165/4885MAOA 143/4885 |
| US-20140256729-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | KDM1A, KDM1B, KDM3B | KDM1A 1/4885MAOB 186/4885MAOA 175/4885 |
| US-20130178520-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | SNCA, PARK7, PNMT | KDM1A 3423/4885MAOB 34/4885MAOA 39/4885 |
| US-20080167351-A1 | Compounds Which Potentiate Glutamate Receptor and Uses Thereof in Medicine | GRIN1, GRM2, GRM1 | KDM1A 3326/4885MAOB 1930/4885MAOA 2383/4885 |
| US-10329256-B2 | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors | KDM1B, KDM1A, KDM2A | KDM1A 2/4885MAOB 165/4885MAOA 143/4885 |
| US-20180079709-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | KDM1A 2/4885MAOB 147/4885MAOA 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.